z-logo
open-access-imgOpen Access
Model‐Informed Drug Development for Everolimus Dosing Selection in Pediatric Infant Patients
Author(s) -
Combes Francois Pierre,
Einolf Heidi J.,
Coello Neva,
Heimbach Tycho,
He Handan,
Grosch Kai
Publication year - 2020
Publication title -
cpt: pharmacometrics and systems pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.53
H-Index - 37
ISSN - 2163-8306
DOI - 10.1002/psp4.12502
Subject(s) - tuberous sclerosis , everolimus , medicine , dosing , pharmacodynamics , pharmacokinetics , refractory (planetary science) , nonmem , population , pediatrics , drug , pharmacology , physics , environmental health , psychiatry , astrobiology
Everolimus is currently approved in Europe as an adjunctive therapy for patients aged ≥ 2 years with tuberous sclerosis complex (TSC)–associated treatment‐refractory partial‐onset seizures, based on the EXIST‐3 study (NCT01713946) results. As TSC‐associated seizures can also affect children aged between 6 months and 2 years, a modeling and simulation (M&S) approach was undertaken to extrapolate exposure (trough plasma concentration (C min )) after a dose of 6 mg/m 2 and reduction in seizure frequency (RSF). A physiologically based pharmacokinetic model using Simcyp was developed to predict C min in adult and pediatric patients, which was then used by a population pharmacodynamic model and a linear mixed effect model to predict short‐term and long‐term efficacy in adults (for validation) and in children, respectively. Based on the results of the M&S study, everolimus at the dose of 6 mg/m 2 is anticipated to be an efficacious treatment in children 6 months to 2 years of age (up to 77.8% RSF) with concentrations within the recommended target range.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here